Top Markets
#1 Islamic Coin Islamic Coin +151.26%
#2 Akedo Akedo +76.66%
#3 Velvet Velvet +52.20%
#4 Glidr Glidr +51.75%
#5 DOVU DOVU +48.24%
#6 Black Phoenix Black Phoenix +33.87%
#7 Cross Cross +32.61%
#8 Cap Cap +20.07%
#9 DoubleZero DoubleZero +16.25%
#10 Movement Movement +9.75%
Coin of the day
Islamic Coin Islamic Coin
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Pozycja w akcjach #39175
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Cena akcji
$0.378
Ostatnia synchronizacja: 2024-05-24
Kapitalizacja rynkowa
$618.41K
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
0.00%
Kraj
US
Handel NeuBase Therapeutics, Inc. (NBSE)

Kategoria

Healthcare
Zyski dla NeuBase Therapeutics, Inc. (NBSE)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych NeuBase Therapeutics, Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy NeuBase Therapeutics, Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE